Invesco S&P 500 Equal Weight Health Care ETF (RSPH) seeks to track the S&P 500 Equal Weight Health Care Index, which measures the performance of healthcare companies within the S&P 500 but assigns equal weights to each stock rather than market-cap weighting. This sector-focused equity ETF provides balanced exposure to pharmaceuticals, biotechnology, medical devices, and healthcare services companies.
How It Works
RSPH uses a passively managed, equal-weight approach that allocates the same percentage to each healthcare stock in the S&P 500, typically around 60-70 holdings. Unlike market-cap weighted funds that favor mega-cap companies like Johnson & Johnson, this methodology gives smaller healthcare firms equal influence on performance. The fund rebalances quarterly to maintain equal allocations, systematically selling outperformers and buying underperformers. This creates a natural value tilt within the healthcare sector.
Key Features
- Equal weighting prevents mega-cap healthcare stocks from dominating returns, giving mid-cap biotech and device companies equal portfolio influence
- Quarterly rebalancing creates systematic buying of healthcare laggards and selling of winners, potentially enhancing long-term returns
- Pure-play healthcare exposure with approximately 60-70 S&P 500 healthcare stocks, avoiding broader market dilution found in diversified funds
Risks
- This ETF can lose significant value during healthcare sector selloffs, potentially declining 20-30% when drug pricing concerns or regulatory changes impact the industry
- Equal weighting means higher exposure to volatile smaller biotech companies compared to market-cap weighted healthcare ETFs, increasing day-to-day price swings
- Sector concentration risk means the fund lacks diversification benefits, moving in lockstep with healthcare industry cycles and regulatory environments
Who Should Own This
Best suited as a satellite holding (5-15% of equity allocation) for investors with 3+ year time horizons seeking targeted healthcare sector exposure with equal-weight methodology. Medium-to-high risk tolerance required due to sector concentration and biotech volatility. Appeals to investors who believe smaller healthcare companies will outperform industry giants over time.